Concepedia

Patrick K. Reville

PK

30

Publications

1.2K

Citations

21

H-Index

1999

Active since

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

Albert Einstein College of Medicine

Harvard University

University of Wisconsin–Madison

Dana-Farber Cancer Institute

Patrick K. Reville is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, pathology, and cancer research.

ORCID

Top concepts

Publications per year

1999–2025

30

Publications

30

Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial

Tapan M. Kadia, Patrick K. Reville, Gautam Borthakur et al. · The Lancet Haematology · 2021 · 166 citations · Full text

, , +11

Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy

Hussein A. Abbas, Dapeng Hao, Katarzyna Tomczak et al. · Nature Communications · 2021 · 128 citations · Full text

Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Tapan M. Kadia, Patrick K. Reville, Xuemei Wang et al. · Journal of Clinical Oncology · 2022 · 107 citations · Full text

Consumption of Soy Isoflavone Enriched Bread in Men with Prostate Cancer Is Associated with Reduced Proinflammatory Cytokines and Immunosuppressive Cells

Gregory B. Lesinski, Patrick K. Reville, Thomas A. Mace et al. · Cancer Prevention Research · 2015 · 82 citations · Full text

, , +15

Hypomethylating agent and venetoclax with FLT3 inhibitor “triplet” therapy in older/unfit patients with FLT3 mutated AML

Musa Yılmaz, Hagop M. Kantarjian, Nicholas J. Short et al. · Blood Cancer Journal · 2022 · 62 citations · Full text

Rows per page

1–5 of 30